MDBH MDB CAPITAL HOLDINGS LLC

New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $400B Brain-Computer Interface (BCI) Market

New PatentVest Pulse Report Maps the Competitive and IP Landscape of the $400B Brain-Computer Interface (BCI) Market

Designed for investors, board members, and CEOs, the latest PatentVest Pulse offers a strategic view of who’s winning—and why—in the emerging BCI market

Dallas, TX, April 01, 2025 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report on brain-computer interfaces (BCIs). Titled ,” the report reveals how control over intellectual property—not just innovation—is shaping the future of neurotechnology.

Neurological disorders represent one of the fastest-growing and highest-need areas in global healthcare, with millions affected by conditions such as paralysis, epilepsy, stroke, and treatment-resistant depression. As traditional treatments struggle to deliver meaningful outcomes, BCIs are emerging as a next-generation solution—restoring lost function, enabling new capabilities, and shifting neurological care from reactive to proactive.

The U.S. market for BCIs is projected to exceed $400 billion. Approximately $80 billion is concentrated in high-acuity, early-adopting patient populations already aligning with clinical and reimbursement pathways. A further $320 billion in long-term potential lies in broader neurological and psychiatric conditions, where early alignment of intellectual property, clinical validation, and commercialization strategy will be critical to scaling. While the opportunity is vast, long-term value will accrue to the companies that move early to secure technical, clinical, and IP leadership.

This report delivers a first-of-its-kind strategic lens into the BCI market—combining deep company-level benchmarking with a comprehensive IP landscape analysis. It profiles the clinical strategies, platform architectures, and patent portfolios of the most prominent BCI players—including Synchron, Neuralink, Blackrock Neurotech, Precision Neuroscience, INBRAIN Neuroelectronics, Paradromics, Axoft, Motif Neurotech, and Science Corp—while mapping over 2,160 patent families across 664 entities to identify the companies, universities, and innovation clusters shaping the future of neurotechnology.

Key Insights:

  • Strategic Leaders Are Emerging: While Neuralink commands visibility, Synchron is quietly establishing category leadership through a minimally invasive platform, global partnerships, and a highly targeted IP strategy spanning 10 jurisdictions. Other leaders—including INBRAIN, Blackrock, Precision Neuroscience, and Paradromics—are staking out defensible positions through differentiated technologies, clinical focus areas, and early IP consolidation.
  • Corporate IP Consolidation: More than 2,160 unique BCI patent families are now held by companies like NeuroPace, Neurolutions, Cognixion, Neurable, Snap (NextMind), Panasonic, Arctop, and CereGate—highlighting an accelerating arms race for control over system-level intellectual property.
  • Universities Still Control the Foundations: Academic institutions such as Tianjin University, Stanford, and the University of California continue to dominate early-stage innovation, holding foundational patents in neural signal processing, interface architecture, and adaptive systems—establishing the starting line for many of today’s commercial efforts.

“Neuralink may command the headlines, but it's companies like Synchron and INBRAIN that are quietly securing the innovation real estate that will shape the future of neurotechnology,” said Will Rosellini, Chief IP Officer at PatentVest. “That’s exactly why we built the PatentVest Pulse—to give boards and investors visibility into the IP dynamics that actually define market leadership, beyond the noise.”

Access the Full Report

The PatentVest Pulse report is now available. Get the data, insights, and strategic intelligence behind the companies shaping the future of BCI: .

For more information or inquiries, please contact .

About PatentVest

PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is the first integrated IP intelligence, strategy, and law firm to enable visionary companies to develop into technology leaders. By combining our proprietary database with a time proven IP diligence process and expert analysis, we deliver actionable insights on the IP landscape to help our clients make informed decisions and stay ahead of the curve. The trends and competitive insights in this report are powered by PatentVest's proprietary IP intelligence platform. Our reports keep a pulse on the key players, technologies, and opportunities shaping deep technology markets.



EN
01/04/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MDB CAPITAL HOLDINGS LLC

 PRESS RELEASE

MDB Capital Holdings Provides 2025 Full Year Update and Shareholder Le...

MDB Capital Holdings Provides 2025 Full Year Update and Shareholder Letter Management to Host Conference Call Today at 4:30 p.m. ET Addison, TX, March 31, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-defining disruptive technology companies, today reported financial and operational results for the fourth quarter and full year ended December 31, 2025. More Detailed Information 2025 Annual Shareholder Letter . Form 10-K . Key Assets and Strategic Developments eXoZymes (NASDAQ: EXOZ): MDB holds appr...

 PRESS RELEASE

PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Ra...

PatentVest Releases New Pulse Report on the $19 Billion Amylin Drug Race Transforming Obesity Treatment Dallas, TX, March 31, 2026 (GLOBE NEWSWIRE) -- PatentVest today released its latest PatentVest Pulse report, “The Amylin Renaissance: Forty Programs, $19 Billion in Deals, and the Race to Build the Next Pillar of Obesity Medicine.” The report provides a comprehensive analysis of the rapidly evolving amylin drug landscape, a mechanism once considered commercially unviable that is now at the center of global pharmaceutical strategy. Over the past eighteen months, more than $19 billion i...

 PRESS RELEASE

PatentVest Highlights New Legal Article on AI Patenting Strategy by Se...

PatentVest Highlights New Legal Article on AI Patenting Strategy by Senior Patent Attorney Sarah Cork Dallas, TX, March 30, 2026 (GLOBE NEWSWIRE) -- PatentVest today announced a new addition to its IP Legal Insights section on the company website, a platform dedicated to sharing expert legal perspectives on intellectual property strategy, emerging technology, and innovation-driven industries. The IP Legal Insights section serves as a resource for founders, executives, and investors seeking to better understand how intellectual property decisions impact innovation, competitive positioning...

 PRESS RELEASE

PatentVest Announces Life Seal Vascular Partnership, Takes Equity Stak...

PatentVest Announces Life Seal Vascular Partnership, Takes Equity Stake in Exchange for IP Intelligence Services IP Strategy and Legal firm backs vascular technology innovator with both expertise and capital commitment Dallas, TX, March 30, 2026 (GLOBE NEWSWIRE) -- PatentVest, a leading provider of IP Strategy and Legal services, today announced a strategic engagement with Life Seal Vascular and disclosed that it has accepted equity in the company as partial consideration for its services. The arrangement reflects PatentVest's conviction in Life Seal Vascular's underlying technology and...

 PRESS RELEASE

MDB Capital Holdings to Host Fourth Quarter and Full Year 2025 Results...

MDB Capital Holdings to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday, March 31, 2026 at 4:30 p.m. Eastern Time Addison, TX, March 23, 2026 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH) (“MDB”), a public venture platform focused on launching category-leading disruptive technology companies, plans to host a Zoom webinar on Tuesday, March 31, 2026 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and full year 2025. A press release detailing the results will be issued prior to the call. Christopher Marlett, CEO and Co-Founde...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch